OK HB2801

Amends 56 O.S. 2021, Section 204 to establish prior authorization requirements for atypical antipsychotic drugs through Oklahoma's vendor drug program.

Requires the Oklahoma Health Care Authority to approve prior authorization requests for FDA-approved atypical antipsychotics not on the preferred drug list for treating mood disorders with psychotic symptoms, bipolar disorders, schizophrenia, and schizotypal or delusion disorders.

Prior authorization approval shall be based on either a trial and failure of any preferred atypical antipsychotic within the preceding 365 days or attestation that the patient is stable on a non-preferred atypical antipsychotic.

Non-preferred atypical antipsychotics covered through prior authorization shall be available at parity to other branded medications in the same class.

The act becomes effective November 1, 2025.